目的合成抗肿瘤新药索拉非尼。
也有人认为索拉非尼可能不是一种全球性的治疗。
Further claims suggesting that sorafenib may not be a global treatment for all sorts of geographic areas.
索拉非尼的疗效通过改善生存期或降低死亡率来衡量。
The efficacy of sorafenib measured as the likelihood to improve survival or reduce mortality was of the same intensity as seen in western trials.
如果患者无法从其它治疗获益，索拉非尼可作为优先选择。
It is a place where patients cannot benefit from those other treatment options that are of higher priorities.
当前索拉非尼在美国和其他国家被批准用来治疗晚期肾细胞癌。
Sorafenib is currently approved in the United States and other countries for treatment of advanced renal cell carcinoma.
治疗时间中位数在索拉非尼组为23周，在安慰剂组为19周。
Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group.
对于已进行了手术的晚期肝癌患者，手术会影响索拉非尼的安全性和疗效吗？
For those patients with advanced HCC, who have had surgical resection, with the surgery impact the safety and efficacy of sorafenib?
目前已有一项将索拉非尼与XX联合的研究，其它联合研究不久也可能出现。
There is now a trial which is combining sorafonib and XX and others will probably come.
根据计划，当中期分析显示索拉非尼的效果明显优于安慰剂时，研究会过早的中止。
The study was stopped prematurely when a planned interim analysis showed sorafenib's significant superiority over placebo.
我们希望索拉非尼能够成为患有这种致命疾病的病人的一个新的极其重要的治疗选择。
We hope to establish Nexavar as an important new treatment option for patients with this devastating disease.
目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。
The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
据拜耳消息，研究人员和投资方目前正在对索拉非尼应用于各种乳腺癌治疗情况进行评测。
Investigators and cooperative groups are currently evaluating sorafenib in various breast cancer treatment Settings, according to Bayer.
国际肝病：令人鼓舞的是索拉非尼在不同地区，东方和西方均显示有效。这在以前是很难证明的吗？
Hepatology Digest: It also seems encouraging that sorafenib has shown efficacy in different regions, both east and west. Is that something that has been difficult to demonstrate before?
但这项研究同时也指出，如果病人先前得到了正规、系统性治疗，那么90%的患者会应用索拉非尼。
But the same study shows that if patients get systemic treatment, then 90% of the patients get treatment with sorafenib.
国际肝病：最近有研究报道索拉非尼用于治疗晚期肝癌，主要是SHARP临床试验和亚太地区的试验。
HEPATOLOGY DIGEST: Recently there were reported studies on the efficacy of sorafenib in treating patients with advanced hepatocellular carcinoma mainly the SHARP trial and the Asia-Pacific study.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼改善了患者生存期，虽然不是很明显，但却是肝癌治疗的一大进步，同时也激发了晚期肝癌一线治疗药物的开发。
The improvement insurvival facilitated by sorafenib, even though modest, was a major advance for the treatment of HCC, and stimulated drug development in first line treatment of HCC.
纽约西奈山医学院的约瑟·劳威特(音译，Josep Llovet)用索拉非尼取得了类似的结果，它是一种针对促进血管生长的蛋白的药剂。
Josep Llovet of the Mount Sinai School of Medicine in New York had a similar outcome with sorafenib, an agent aimed at a protein that promotes blood-vessel growth.
纽约西奈山医学院的约瑟·劳威特(音译，Josep Llovet)用索拉非尼取得了类似的结果，它是一种针对促进血管生长的蛋白的药剂。
Josep Llovet of the Mount Sinai School of Medicine in New York had a similar outcome with sorafenib, an agent aimed at a protein that promotes blood-vessel growth.
应用推荐